Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2024-11-04 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
RP11 SRC Approves Dose Escalation to Final Patient Cohort 3 pages 278.0KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics regarding the approval by the Safety Review Committee to escalate dosing in a clinical trial for their drug candidate VP-001. It discusses clinical trial progress, safety data, and future plans for FDA engagement. The document is a corporate announcement about clinical trial updates and drug development progress, not a financial report, regulatory filing, or shareholder meeting material. It does not contain financial statements, earnings data, or governance information. It is a typical clinical trial update press release, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2024-11-04 English
First ADOA Patient Dosed in Clinical Trial 4 pages 303.8KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics about dosing the first patient in a clinical trial for a drug candidate targeting Autosomal Dominant Optic Atrophy (ADOA). It provides details about the clinical trial design, drug candidate, and future plans for the study. The document is dated 1 November 2024 and includes references to previous ASX announcements and regulatory designations. It does not contain financial statements, earnings data, or detailed management analysis. It is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. The document length is 9067 characters, which is substantial but the content is clearly an update on clinical trial progress. This fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical development progress and does not fit other more specific categories like earnings release, capital update, or management report.
2024-10-31 English
Presentation of RP11 Single Dose Data at RANZCO 3 pages 244.3KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 31 October 2024 from PYC Therapeutics about the presentation of clinical trial data (single dose study of VP-001) at an upcoming medical conference (RANZCO meeting). It describes the drug candidate, disease background, and upcoming presentation details. There are no financial statements, regulatory filings, or detailed financial data. The document is a corporate announcement about a scientific presentation, not a financial report or regulatory filing. It is not an earnings release, annual report, or investor presentation. It is a general regulatory announcement about upcoming data presentation, fitting best under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other categories.
2024-10-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 670.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 2024 SHAREHOLDER UPDATE' and provides detailed operational and clinical progress updates for the third quarter of 2024. It includes financial data such as cash on hand, R&D payments, and a detailed Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows. The document contains substantive financial data and analysis for the quarter ended 30 September 2024, including cash flows from operating, investing, and financing activities. It is not merely an announcement of a report but contains actual financial statements and operational commentary for the quarter. The presence of the Appendix 4C and the quarterly financial data aligns with the characteristics of an Interim / Quarterly Report. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q3 2024
2024-10-24 English
Interim Update on Progress in RP11 Repeat Dose Trials 3 pages 292.8KB
Interim / Quarterly Report Classification · 90% confidence The document is an ASX announcement dated 22 October 2024 from PYC Therapeutics providing an interim update on progress in clinical trials for their drug candidate VP-001 targeting Retinitis Pigmentosa type 11 (RP11). It discusses ongoing clinical studies, safety and efficacy observations, and plans for further updates in the first half of 2025. The content is focused on clinical trial progress and interim results rather than a full financial report or earnings release. It is not a full interim or quarterly report since it lacks comprehensive financial statements or substantive financial data. It is also not a regulatory filing, call transcript, or any other specific category. The document is a progress update on clinical trials, which fits best under Interim / Quarterly Report (IR) as it provides substantive operational and clinical progress data for a period shorter than a full fiscal year. The document length (7563 characters) supports it being a report rather than a brief announcement or publication notice. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q4 2024
2024-10-21 English
US FDA Grants Orphan Drug Designation to PYC Drug Candidate 3 pages 248.8KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics about the US FDA granting Orphan Drug Designation to their drug candidate VP-001. It discusses regulatory status, clinical trial progress, and benefits of the designation. The document is relatively short (6172 characters) and reads as a news release or regulatory announcement rather than a detailed financial or operational report. There are no financial statements, detailed management discussion, or comprehensive data typical of Annual Reports, Interim Reports, or Earnings Releases. It is not a call transcript, board change, or legal proceeding update. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about a significant development but does not constitute a full report or financial disclosure. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-10-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.